Galectin-3 in ambulatory patients with heart failure results from the HF-ACTION study

Circulation: Heart Failure

Volumn 5, Issue 1, 2012, Pages 72-78

  Felker, G Michael ^a   Fiuzat, Mona ^a   Shaw, Linda K ^a   Clare, Robert ^a   Whellan, David J ^b   Bettari, Luca ^c   Shirolkar, Shailesh C ^a   Donahue, Mark ^a   Kitzman, Dalane W ^d   Zannad, Faiez ^e   Pina, Ileana L ^f   O'Connor, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d WAKE FOREST UNIVERSITY   (United States)

^e UNIVERSITÉ DE LORRAINE   (France)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Biomarker; Heart failure; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CAUSE OF DEATH; DISEASE FREE SURVIVAL; ETHNICITY; EXERCISE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FOLLOW UP; KINESIOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CREATININE; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84859639923     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.963637     Document Type: Article

References (14)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics: 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
3. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ. 2005;330:625.
4. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110: 3121-3128. (Pubitemid 39492008)
5. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217-1224. (Pubitemid 44345127)
6. de Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68.
7. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the Deal-HF study. Clin Res Cardiol. 2010;99:323-328.
8. Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: High levels are associated with all-cause mortality. Int J Cardiol. 2011;150:361-364.
9. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011; 108:385-390.
10. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN, on behalf of the Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-Heft) data. Clin Chem. 2006;52:1528-1538. (Pubitemid 44148316)
11. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
12. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarkerguided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422-430.
13. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826-832.
14. Gullestad L, Ueland T, Nymo SH, Kjekshus J, Hulte J, Munthendam P, Adourian A, McMurray JJV, Wikstrand J, Aukrust P. Galectin-3 predicts mortality and response to statin therapy in chronic heart failure. Eur Heart J. 2011;32:297.